Corline Biomedical AB (CLBIO) — Working Capital to Net Assets Ratio
Corline Biomedical AB (CLBIO) has a Working Capital to Net Assets ratio of 20.4% as of December 2025. Working capital of Skr19.16 Million (current assets of Skr23.98 Million minus current liabilities of Skr4.82 Million) is measured against net assets of Skr93.76 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See CLBIO financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Corline Biomedical AB Working Capital to Net Assets (2012–2025)
This chart shows how Corline Biomedical AB's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 20.4%, reflecting working capital of Skr19.16 Million against net assets of Skr93.76 Million SEK. See how many days can Corline Biomedical AB fund operations to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Corline Biomedical AB (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Corline Biomedical AB from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of Corline Biomedical AB.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 20.4% | Skr19.16 Million | Skr93.76 Million | Skr23.98 Million | Skr4.82 Million | ▲ +5.3 pp |
| 2024 | 15.2% | Skr13.20 Million | Skr86.91 Million | Skr21.04 Million | Skr7.85 Million | ▼ -3.0 pp |
| 2023 | 18.2% | Skr17.01 Million | Skr93.32 Million | Skr23.80 Million | Skr6.79 Million | ▼ -12.2 pp |
| 2022 | 30.5% | Skr28.80 Million | Skr94.59 Million | Skr36.00 Million | Skr7.19 Million | ▼ -7.9 pp |
| 2021 | 38.4% | Skr35.39 Million | Skr92.23 Million | Skr44.82 Million | Skr9.43 Million | ▲ +29.7 pp |
| 2020 | 8.6% | Skr4.49 Million | Skr52.03 Million | Skr10.74 Million | Skr6.25 Million | ▼ -26.0 pp |
| 2019 | 34.7% | Skr20.56 Million | Skr59.32 Million | Skr24.99 Million | Skr4.43 Million | ▼ -3.6 pp |
| 2018 | 38.3% | Skr21.04 Million | Skr54.96 Million | Skr28.99 Million | Skr7.95 Million | ▲ +10.1 pp |
| 2017 | 28.2% | Skr12.94 Million | Skr45.93 Million | Skr18.44 Million | Skr5.50 Million | ▲ +0.4 pp |
| 2016 | 27.8% | Skr10.78 Million | Skr38.75 Million | Skr13.31 Million | Skr2.53 Million | ▲ +19.3 pp |
| 2015 | 8.6% | Skr1.82 Million | Skr21.25 Million | Skr5.56 Million | Skr3.74 Million | ▲ +175.0 pp |
| 2014 | -166.5% | Skr-9.13 Million | Skr5.48 Million | Skr2.16 Million | Skr11.29 Million | ▼ -120.6 pp |
| 2013 | -45.9% | Skr-3.67 Million | Skr8.00 Million | Skr1.83 Million | Skr5.50 Million | ▲ +500.7 pp |
| 2012 | -546.6% | Skr-7.50 Million | Skr1.37 Million | Skr3.59 Million | Skr11.09 Million | — |